Amanda A. Bouffard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda A. Bouffard has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Marcela V. Maus
Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States
93 shared publications - Mark B. Leick
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts
90 shared publications - Filippo Birocchi
Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States
87 shared publications - Diego Salas-Benito
Krantz Family Center for Cancer Research and Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA
86 shared publications - Trisha R. Berger
Krantz Family Center for Cancer Research and Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA
76 shared publications - Michael C. Kann
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
63 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e016839
Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products
In relapsed/refractory multiple myeloma, the approved B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell product ciltacabtagene autoleucel (cilta-cel) shows higher response rates than idecabtagene vicleucel (ide-cel) in pivotal trials and real-world comparisons. This advantage has been attributed to the biparatopic dual-VHH (dVHH) binder of cilta-cel. However, the products also differ in the gene regulatory elements driving CAR expression: cilta-cel uses a human elongation factor α (EF1α) promoter in conjunction with a woodchuck hepatitis post-transcriptional regulatory element (EF1α +WPRE ), whereas ide-cel uses a myeloproliferative sarcoma virus enhancer (MND) promoter without WPRE (MMD -WPRE ). The role of these elements in CAR-T cell efficacy remains unexplored. We generated lentiviral vectors where the CAR transgene was composed of either a dVHH-based or a single-chain variable fragment (scFv)-based BCMA-CAR with a 4-1BB costimulatory and a CD3ζ signaling domain, expressed either by EF1α +WPRE or MND -WPRE . Primary human T cells or a nuclear factor of activated T cells (NFAT)-GFP Jurkat reporter line were compared at matched vector copy numbers (VCN) or CAR surface expression. Antitumor efficacy was assessed in MM.1S-engrafted NSG mice. When transduced at the same multiplicities of infection, MND -WPRE CAR-T cells reached higher VCN and transduction rates than EF1α +WPRE regardless of the binder type. In an NFAT-GFP reporter assay, unstimulated MND -WPRE -driven cells showed higher NFAT and CD69 expression, consistent with greater tonic signaling compared with EF1α +WPRE . In vivo, independently of the BCMA binder moiety, EF1α +WPRE -driven CAR-T cells demonstrated superior cytokine secretion and tumor control along with greater survival of mice treated with EF1α +WPRE compared with MND -WPRE -driven CAR-T cells. CAR-T cells expressing the CAR under MND -WPRE showed greater gene transfer during manufacturing, but this did not translate into superior function in vivo. The advantage attributed to cilta-cel’s dual VHH binder was lost when expressed under MND -WPRE and, conversely, ide-cel’s scFv binder achieved better antitumor activity when expressed under EF1α +WPRE than under MND -WPRE . The efficacy difference between our CAR constructs in xenograft models therefore tracked with the choice of regulatory elements driving CAR expression independently of the binder. It may be better to choose gene regulatory elements based on the CAR-T cell function they confer rather than on expression strength alone.
- 18 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e016839
Open AccessGene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products
In relapsed/refractory multiple myeloma, the approved B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell product ciltacabtagene autoleucel (cilta-cel) shows higher response rates than idecabtagene vicleucel (ide-cel) in pivotal trials and real-world comparisons. This advantage has been attributed to the biparatopic dual-VHH (dVHH) binder of cilta-cel. However, the products also differ in the gene regulatory elements driving CAR expression: cilta-cel uses a human elongation factor α (EF1α) promoter in conjunction with a woodchuck hepatitis post-transcriptional regulatory element (EF1α +WPRE ), whereas ide-cel uses a myeloproliferative sarcoma virus enhancer (MND) promoter without WPRE (MMD -WPRE ). The role of these elements in CAR-T cell efficacy remains unexplored. We generated lentiviral vectors where the CAR transgene was composed of either a dVHH-based or a single-chain variable fragment (scFv)-based BCMA-CAR with a 4-1BB costimulatory and a CD3ζ signaling domain, expressed either by EF1α +WPRE or MND -WPRE . Primary human T cells or a nuclear factor of activated T cells (NFAT)-GFP Jurkat reporter line were compared at matched vector copy numbers (VCN) or CAR surface expression. Antitumor efficacy was assessed in MM.1S-engrafted NSG mice. When transduced at the same multiplicities of infection, MND -WPRE CAR-T cells reached higher VCN and transduction rates than EF1α +WPRE regardless of the binder type. In an NFAT-GFP reporter assay, unstimulated MND -WPRE -driven cells showed higher NFAT and CD69 expression, consistent with greater tonic signaling compared with EF1α +WPRE . In vivo, independently of the BCMA binder moiety, EF1α +WPRE -driven CAR-T cells demonstrated superior cytokine secretion and tumor control along with greater survival of mice treated with EF1α +WPRE compared with MND -WPRE -driven CAR-T cells. CAR-T cells expressing the CAR under MND -WPRE showed greater gene transfer during manufacturing, but this did not translate into superior function in vivo. The advantage attributed to cilta-cel’s dual VHH binder was lost when expressed under MND -WPRE and, conversely, ide-cel’s scFv binder achieved better antitumor activity when expressed under EF1α +WPRE than under MND -WPRE . The efficacy difference between our CAR constructs in xenograft models therefore tracked with the choice of regulatory elements driving CAR expression independently of the binder. It may be better to choose gene regulatory elements based on the CAR-T cell function they confer rather than on expression strength alone.
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary Table 5. The results of the statistical analysis used to assess additive vs synergistic effect of PD1-blockade antibody in combination with CAR-T cells is shown for Fig 6D.
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary Table 5. The results of the statistical analysis used to assess additive vs synergistic effect of PD1-blockade antibody in combination with CAR-T cells is shown for Fig 6D.
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Ibrutinib-mediated ITK inhibition in CAR-T cells in vitro.
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Ibrutinib-mediated ITK inhibition in CAR-T cells in vitro.
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Material S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary statistical code
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary statistical code
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary Table 2. The results of the statistical analysis used to assess additive vs synergistic effect of ibrutinib in combination with CAR-T cells is shown for Fig 4H.
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary Table 2. The results of the statistical analysis used to assess additive vs synergistic effect of ibrutinib in combination with CAR-T cells is shown for Fig 4H.
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
In vitro CAR-T cell-mediated cytotoxicity and in vivo CAR-T cell immunophenotype following aderbasib treatment.
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
In vitro CAR-T cell-mediated cytotoxicity and in vivo CAR-T cell immunophenotype following aderbasib treatment.
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary Table 4. The results of the statistical analysis used to assess additive vs synergistic effect of ibrutinib in combination with CAR-T cells is shown for Fig 5B.
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary Table 4. The results of the statistical analysis used to assess additive vs synergistic effect of ibrutinib in combination with CAR-T cells is shown for Fig 5B.
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
In vivo immunophenotypic analysis and therapeutic efficacy of meso-CAR-T cell monotherapy or in combination with ibrutinib against pancreatic tumors.
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
In vivo immunophenotypic analysis and therapeutic efficacy of meso-CAR-T cell monotherapy or in combination with ibrutinib against pancreatic tumors.
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Body weight measurements in mice treated with ibrutinib.
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Body weight measurements in mice treated with ibrutinib.
- Open Access
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary Table 1. The results of the statistical analysis used to assess additive vs synergistic effect of ibrutinib in combination with CAR-T cells is shown for Fig 4C.
- 8 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Supplementary Table 1. The results of the statistical analysis used to assess additive vs synergistic effect of ibrutinib in combination with CAR-T cells is shown for Fig 4C.